<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcitonin gene-related peptide receptor or ligand (CGRP) antagonists for preventive treatment of migraine in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcitonin gene-related peptide receptor or ligand (CGRP) antagonists for preventive treatment of migraine in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Calcitonin gene-related peptide receptor or ligand (CGRP) antagonists for preventive treatment of migraine in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="23%"></colgroup> <colgroup width="31%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Dose (range)</td> <td class="subtitle1">Maximum dose</td> <td class="subtitle1">Notes</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Parenteral monoclonal antibodies*</td> </tr> <tr> <td class="indent1">Erenumab</td> <td>70 to 140 mg SUBQ once monthly</td> <td>140 mg SUBQ once monthly</td> <td> <ul> <li>Auto-injector</li> </ul> </td> </tr> <tr> <td class="indent1">Fremanezumab</td> <td> <p>225 mg SUBQ once monthly</p> <p>-OR-</p> 675 mg SUBQ once every 3 months</td> <td> <p>225 mg SUBQ once monthly</p> <p>-OR-</p> 675 mg SUBQ once every 3 months</td> <td> <ul> <li>Auto-injector</li> <li>Dosing monthly or every 3-month interval</li> </ul> </td> </tr> <tr> <td class="indent1">Galcanezumab</td> <td>120 mg SUBQ once monthly (following initial 240 mg SUBQ loading dose)</td> <td>120 mg SUBQ once monthly</td> <td> <ul> <li>Auto-injector</li> <li>May also be used for cluster headache suppression (dosing regimen differs)</li> </ul> </td> </tr> <tr> <td class="indent1">Eptinezumab</td> <td>100 to 300 mg IV infusion once every 3 months</td> <td>300 mg IV infusion once every 3 months</td> <td> <ul> <li>IV infusion over ≥30 minutes (in clinic)</li> <li>Dosing every 3 months</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Oral small molecule antagonists</td> </tr> <tr> <td class="indent1">Atogepant</td> <td> <p><strong>Episodic migraine:</strong> 10 mg, 30 mg, or 60 mg orally once daily</p> <strong>Chronic migraine:</strong> 60 mg orally once daily</td> <td>60 mg orally once daily</td> <td> <ul> <li>Dose adjustment required for kidney impairment</li> <li>Significant drug interactions<sup>¶</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Rimegepant</td> <td><strong>Episodic migraine:</strong> 75 mg orally every <strong>other</strong> day</td> <td>75 mg orally every <strong>other</strong> day</td> <td> <ul> <li>May also be used for acute migraine treatment (dosing regimen differs)</li> <li>Orally disintegrating tablet</li> <li>Dose adjustment required for kidney impairment</li> <li>Significant drug interactions<sup>¶</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">CGRP antagonists may be effective preventive treatment for patients with marked disability from frequent migraines and/or those who do not respond to other preventive agents. Long-acting intravenous and subcutaneous formulations may be preferred by patients who have difficulty with daily preventive therapy. CRGP antagonists are avoided in patients with significant cardiovascular disease and pregnancy. Refer to UpToDate and Lexicomp drug monographs for full clinical use, precautions, and additional dosing details.</div><div class="graphic_footnotes"><p>P-gp: P-glycoprotein drug efflux pump; CYP3A4: cytochrome p450 3A4 isoform; SUBQ: subcutaneous; IV: intravenous.</p>
<p>* Injection site reactions and constipation are most frequently reported adverse effects for parenteral agents.</p>
¶ Small molecule "gepants" undergo CYP3A4 metabolism and are substrates of P-gp efflux pump. Specific interactions may warrant dose adjustment or avoidance of some combinations. To determine potential interactions for a specific patient's medication list, use the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_reference">Data from: Lexicomp Online (Lexi-Interact). Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 141581 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
